CLINICAL AND EPIDEMIOLOGICAL FEATURES OF COMPLEX APPROACHES IN THE TREATMENT OF OSTEOPOROSIS IN SYSTEMIC SCLERODERMA

Diseases of osteoporosis and the assessment of the patient is taken from the degree of fracture as a marker of many diseases. But bone mineral density (SMZ) is also associated with disease and the risk of fracture. Metabolic disorders associated with secondary osteoporosis are 2-3 times higher in women and in men with hip fractures and vertebral fractures. Globally, osteoporosis is the most common metabolic, bone disease, affecting more than 200 million people worldwide. In Europe, the United States and Japan, 75 million people are diagnosed with osteoporosis. As SMZ decreases, osteoporosis increases with age. Senile osteoporosis is more common in people over 70 years of age. Secondary osteoporosis can occur in any person. Although bone loss in women begins gradually, it accelerates menopause, with delivery at age 50 and beyond. The incidence of postmenopausal osteoporosis is highest in 50-70 women. Women are higher on osteoporosis. Half of postmenopausal women have fractures associated with life and osteoporosis; Ush develops a spinal deformity in 25% of women, and 15% experience hip fractures. Hip fractures are similar in different ethnicities